<DOC>
	<DOCNO>NCT00852189</DOCNO>
	<brief_summary>This Phase 1 clinical trial evaluate safety tolerability escalate dos EC0489 patient refractory metastatic tumor exhaust standard therapeutic option .</brief_summary>
	<brief_title>Study EC0489 Treatment Refractory Metastatic Tumors</brief_title>
	<detailed_description>This Phase 1 , dose escalation study EC0489 administer intravenous bolus ( IV ) week 1 3 4-week cycle PART A weekly 4-week cycle PART B . Both Parts open patient refractory metastatic cancer exhaust standard therapeutic option . EC0489 drug specifically design enter cell via folate vitamin receptor . Experimental evidence show target receptor over-expressed many human cancer . There previous human study EC0489 ; however , lab research ( research test tube animal ) use EC0489 show activity tumor animal . This activity animal model suggest EC0489 may useful chemotherapy human cancer . The primary objective study determine safety maximum tolerate dose EC0489 give intravenous bolus . The efficacy treatment also measure .</detailed_description>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>18 year age old Histological cytological diagnosis neoplasm No effective standard therapeutic option ECOG performance status 02 â‰¥ 4 week post therapeutic radiation recover ( returned baseline ) acute toxicity associate prior cytotoxic therapy . Patients previously treat noncytotoxic therapy ( e.g. , EGFR , VGEF , etc . ) recover control drugassociated toxicity allow enter trial period consist 4 halflives agent . Negative serum pregnancy test woman childbearing potential within one week prior treatment investigational agent ( 99mTcEC20 EC0489 ) willingness practice contraceptive method Adequate bone marrow reserve , renal hepatic function Concurrent malignancy Women pregnant breastfeed Evidence symptomatic brain metastasis Receiving concomitant anticancer therapy ( exclude supportive care ) Requires palliative radiotherapy time study entry Requires antifolate therapy comorbid condition Heart failure characterize great NYHA Class I History myocardial infarct Any follow baseline echocardiogram finding : valvular lesion ( stenosis insufficiency ) characterize great moderate , systolic ventricular impairment characterize great mild , leave ventricular ejection fraction &lt; 55 % , feature echocardiogram would confound interpretation serial echocardiogram require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>EC0489</keyword>
	<keyword>EC20</keyword>
	<keyword>Refractory</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Experimental</keyword>
</DOC>